P-glycoprotein inhibitors as an adjunct therapy for TB

Area of Science:

• Microbiology
• Pharmacology
• Immunology

Background:

• Multidrug-resistant tuberculosis (MDR-TB) poses a significant therapeutic challenge.
• Upregulation of efflux pumps, particularly P-glycoprotein (P-gp), and angiogenesis contribute to MDR-TB.
• P-gp hinders drug bioavailability, while angiogenesis complicates drug delivery to TB granulomas.

Purpose of the Study:

• To review the mechanisms by which P-gp and angiogenesis contribute to MDR-TB.
• To explore the potential of P-gp inhibitors and anti-angiogenic drugs in improving TB treatment.
• To discuss adjunct therapies for shortening TB treatment duration.

Main Methods:

• Review of existing literature on P-gp, angiogenesis, and their roles in TB.
• Analysis of studies investigating P-gp inhibitors (e.g., verapamil) and anti-angiogenic drugs (e.g., bevacizumab) in TB models.
• Discussion of the combined effects of these interventions on drug delivery and treatment outcomes.

Main Results:

• TB infection upregulates both P-gp expression and angiogenic factors.
• Combined P-gp and anti-angiogenic strategies show promise in enhancing drug delivery to granulomas.
• P-gp inhibitors and anti-angiogenic agents have demonstrated potential in improving TB drug bioavailability and efficacy.

Conclusions:

• Targeting P-gp and angiogenesis represents a promising strategy to combat MDR-TB.
• Adjunct therapy with P-gp inhibitors could potentially shorten the duration of TB treatment.
• Further research into combined therapeutic approaches is warranted to overcome MDR-TB challenges.